Earnings Call Transcript for quarter ended June 30, 2026

AI summary - Q1 FY27 revenue INR69 Cr, +5% y-y; EBITDA margin ~22% - SteriPort platform now 44% of revenue; capacity expanding from 6.6 Cr to 12 Cr bottles/year, commissioning delayed to Q2 FY27 - SVP facility to start operations by Q4 FY27, focusing on export markets with high-margin products - Captive 10.8 MW solar power plant commissioned June 2026, expected to reduce power costs and improve margins - FY27 SteriPort Line 3 peak revenue expected INR110-120 Cr annualized, with EBITDA margin expansion of 4-5% including solar savings - FY28 peak revenue target INR425 Cr with EBITDA margin 25-26% - Incremental depreciation from new lines approx INR6 Cr annually - Working capital days ~141 due to quarantine requirements; debt expected to reduce by INR30-35 Cr annually - Focus on sterile dosage forms with pipeline of 20 products in inhalation, ophthalmics, and diluents for advanced markets - Incremental ROCE for SteriPort line ~16-17%, SVP ~14-15%; effective tax rate ~26%